Clinical trial results are massive share price catalysts for biotechs. NTI has three different trials completing over the next 12 months. One of them is expected in the next couple of weeks.
$0.073
Opened: 18-Sep-2023
Shares Held at Open: 8,400,000
What does NTI do?
Neurotech International (ASX: NTI) is a clinical stage biotech company.
NTI is advancing clinical trials targeting rare and severe neurological disorders predominantly in children.
NTI’s primary treatment is a cannabinoid derived biopharmaceutical called NTI164. NTI is seeking to prove it is a both safe and effective treatment for disorders such as Autism Spectrum Disorder, Rett Syndrome, PANDAS/PAN and Cerebral Palsy.
What is the macro theme?
Paediatric neurological disorders are not getting as much attention from biotech companies as they should, but luckily there are government incentives for companies developing treatments for these disorders.
The impact to families who have children with these disorders is significant and society more generally bears a large cost in supporting these families. Moreover, some treatments can have bad side effect profiles or suboptimal efficacy.
NTI’s clinical trials are for disorders of the brain and spinal cord, mostly in children, across potential orphan drug indications for rare conditions, such as Rett Syndrome as well as disorders that have larger total addressable markets such as Autism Spectrum Disorder (ASD). Both avenues to market for NTI164 could prove lucrative, assuming the trials are successful.
As is often the case, biotechs that successfully complete clinical trials can generate sustained re-rates as positive data comes out, regulatory approvals are granted and commercialisation agreements are made.
We think that companies that can improve on existing standards of care across both safety and efficacy will attract capital in the market due to their ability to improve both quality of life and health economics.
Why did we invest in NTI?
NTI has significant material newsflow in the next 6-12 months across 3 trials
Clinical trial results are massive share price catalysts for biotechs. NTI has three different trials completing over the next 12 months. One of them is expected in the next couple of weeks.
NTI is targeting “orphan” diseases - treatments that are highly valuable
NTI is currently targeting PANDAS/PANS and Rett Syndrome, which are potentially eligible for orphan drug designation. The average price for an orphan drug is US$32,000 per year per patient and government approvals to market are fast tracked.
NTI is following the same strategy as the $1.4BN capped Neuren
Neuren Pharmaceuticals’ share price re-rated by more than 1,300% (~$100M market cap to $1.4BN market cap). Neuren developed a successful treatment for Rett Syndrome and is working on other orphan diseases. NTI is unashamedly trying to replicate Neuren’s path to success. We like this approach.
Strong safety profile, is NTI’s treatment better than $1.4BN Neuren?
If NTI’s upcoming Rett Syndrome trial shows its treatment is SAFER than $1.4BN Neuren’s “claim to fame” Rett Syndrome treatment, we think NTI can take a big chunk of the market (and hopefully get to a similar $1.4BN market cap).
Promising efficacy data at treating Autism, large addressable market
If NTI’s treatment is proven safe and effective for Autism Spectrum Disorder (ASD), we think it could become an important part of the overall care for ASD sufferers, which is 1 in 100 children.
NTI Management track record
NTI’s Executive Director is Dr Tom Duthy, who is also Chairman of Arovella Therapeutics, another one of our Portfolio Companies, which grew from a low of 2 cents to a high of 10.5 cents between January and April 2023. We like to follow management that has delivered for us in the past.
Successful fund, Merchant Group has a substantial position in NTI
Merchant Group became a substantial shareholder of NTI with a 5.01% stake when NTI was trading at ~9 cents. We have followed Merchant Group’s investments closely and think the fund has a keen eye for high potential biotechs given its past history of success.
What do we expect NTI to deliver?
Objective #1: Rett Syndrome clinical trials
NTI is currently undertaking a Phase I/II trial that will test the safety and efficacy of NTI’s treatment for a rare genetic neurological and developmental disorder called Rett Syndrome.
This is the same disease that Neuren Pharmaceuticals commercialised a treatment for which helped take Neuren to a ~$1.4BN market cap.
NTI’s trial is aiming to improve on Neuren’s results across safety and efficacy, after dosing the first patient in this trial in August 2023.
Milestones
Last patient dosed for Phase I/II
Results (anticipated Q1 CY2024)
Objective #2: Autism Spectrum Disorder (ASD) clinical trials
After a successful Phase I/II trial demonstrated the safety of NTI’s treatment in 2023, and showed promising signs on its efficacy, NTI launched a larger Phase II/III trial for ASD.
We expect NTI to complete recruitment for this trial before the end of 2023.
Milestones
Completion of patient recruitment (H2 CY2023)
Last patient dosed
Results (Q1 CY2024)
Objective #3: PANDAS/PANS clinical trial
This Phase I/II clinical trial is testing the safety and efficacy of NTI’s treatment for a rare paediatric neurological disorder sometimes associated with Streptococcal infections called PANDAS/PANS.
Milestones
Results (mid-late September CY2023)
Objective #4: Cerebral Palsy clinical trials
NTI intends to launch a Phase I/II clinical trial for Cerebral Palsy in 2H CY2023. We see this as a source of additional upside for NTI over the long term.
Milestones
HREC Approval and TGA clearance
First patient recruited
Completion of patient recruitment
Last patient dosed
Results
Objective #5: Advance commercialisation through licensing/partnerships
We want to see NTI advance commercialisation initiatives at this early stage, and ideally accelerate these initiatives pending clinical trial results. This could be a source of additional capital for the business.
Milestones
Sign a licensing/partnership agreement with another larger company
What could go wrong?
Clinical trial risk
It is important to be aware that clinical trials can be unsuccessful.
In particular, there are some standard risks that are associated with biotechs that are undertaking clinical research:
There is a chance that one or more of NTI’s clinical trials fail to meet their primary or secondary endpoints, meaning the treatments fail to satisfy the criteria of the studies. Any clinical trial results, if negative, could hurt the NTI share price.
Competition risk
NTI will need to move quickly to establish its presence in the market. If progress is slow, alternative treatments could emerge hurting NTI’s prospects.
Funding risk
Pre revenue biotech companies regularly need to raise capital to fund their growth ambitions. Capital raises can cause dilution to existing shareholders.
NTI will likely need to raise capital at some stage in the future, potentially at a discount to market prices to secure funds. This will be contingent on clinical trial results and broader market sentiment (see next risk).
Market risk
Broader market sentiment for small pre-revenue biotechs could get worse and the sector as a whole trades lower, taking NTI’s share price with it. Alternatively, the entire market could sell down as well.
What is our investment plan?
Our Investment Plan for NTI is to hold on to a majority of our position to see the company execute on its business strategy over the next two to three years.
If the company’s share price materially re-rates in the medium term due to the results of any of the clinical trial results, a macro triggering event or any other unknown reason, we may look to sell up to ~20% of our holding. See our general disclosure policy for more details.
Disclosure: Disclosure: S3 Consortium Pty Ltd (the Company) and Associated Entities own 8,400,000 NTI shares at the time of publishing this article. The Company has been engaged by NTI to share our commentary on the progress of our Investment in NTI over time.
NTI’s trial of Autism treatment in children shows further patient improvement after 12 weeks.
Jul 11, 2024
Jul 11, 2024 |
15 min
There are currently no approved treatments available to help children with Autism Spectrum Disorder (ASD). Our biotech Investment Neurotech International (ASX: NTI) is looking to change this.
NTI’s Phase I/II Rett Syndrome clinical trial results improve upon $2.4BN capped Neuren’s results…
May 6, 2024
May 6, 2024 |
10 min
Our biotech Investment, Neurotech International (ASX: NTI) just announced additional data from its Rett Syndrome clinical trial today.
NTI’s two clinical trial results are in - Treatment success for BOTH Autism AND for Rett Syndrome
Apr 17, 2024
Apr 17, 2024 |
13 min
Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.
TWO major share price catalysts… in the coming weeks
Mar 20, 2024
Mar 20, 2024 |
21 min
We are Invested in Neurotech International (ASX: NTI) - a clinical stage biotech company.
US Short Report questions Acadia’s safety - NTI’s competing treatment safety results due within 6 weeks
Feb 19, 2024
Feb 19, 2024 |
14 min
Neurotech International (ASX: NTI) is currently running a Phase I/II clinical trial for Rett Syndrome.
NTI’s autism data is still improving…big implications
Jul 18, 2024
Jul 18, 2024 |
3 min
Our biotech Investment, Neurotech International (ASX: NTI) reported positive secondary endpoint data from its Phase II/III autism trial today.
NTI Autism results get even better out to 12 weeks
Jul 10, 2024
Jul 10, 2024 |
3 min
Neurotech International (ASX :NTI) just reported that further analysis of its Phase II/III autism trial showed patients receiving NTI164 experienced significant additional improvements from week 8 to week 12.
A potential fast-track to market for NTI's drug candidate
Jul 9, 2024
Jul 9, 2024 |
2 min
Today, our biotech Investment, Neurotech International (ASX: NTI) has filed for Orphan Drug Designation with the US FDA for its drug candidate NTI164 to treat the rare neurological disorders PANDAS and PANS in children and adults.
NTI appoints Chief Medical Officer
Jul 5, 2024
Jul 5, 2024 |
2 min
Our Biotech Investment Neurotech International (ASX: NTI) has appointed Associate Professor Carolyn Ellaway as its inaugural Chief Medical Officer.
NTI sets up expert panel after TGA meeting
Jun 28, 2024
Jun 28, 2024 |
4 min
Today, our biotech Investment, Neurotech International (ASX: NTI) established an expert advisory group to provide guidance on its PANDAS/PANS drug development program following productive discussions with the Australian Therapeutic Goods Administration (TGA).
Are we Beyond The bear-zone...?
Jul 21, 2024
Jul 21, 2024 |
17 min
It’s week three of our “is the small cap market back?” watch. A quieter week this week, not as green as the first two weeks of July. But also not that red at all - more grey.
And will it Continue...?
Jul 13, 2024
Jul 13, 2024 |
13 min
We’ll try not to jinx it. But this was the second week in a row where our Portfolio and watchlist was more green than red…
Small Cap market is looking good… and are share price re-rates back?
Jun 1, 2024
Jun 1, 2024 |
13 min
So what is the state of play in the micro cap end of the market right now? We think the window to deliver good news AND be rewarded with a rerate is definitely open…
Life Back in the Small Caps Market
May 11, 2024
May 11, 2024 |
14 min
What a great, green week in small cap stocks. The market has actually felt positive again.
Macro Themes are Boosting the Markets
Apr 20, 2024
Apr 20, 2024 |
16 min
The small cap market has been a hive of activity this week.